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 Oxidative stress, the cellular damage caused by reactive
oxygen species (ROS), is implicated in a series of ocular dis-
eases such as cataract [1], glaucoma [2], uveitis [3], retrolen-
tal fibroplasias [4], diabetic retinopathy [5], and age-related
macular degeneration (AMD) [6]. The retina is most suscep-
tible to oxidative damage due to its higher oxygen consump-
tion than any other tissue, exposure to cumulative irradiation,
and abundance of photosensitizers and polyunsaturated fatty
acids that can initiate cytotoxic chain-reactions [7]. The reac-
tive oxygen species generated in the retina are normally detoxi-
fied by antioxidants including superoxide dismutase (SOD),
catalase, and glutathione peroxidase [7]. Superoxide dismutase
1 (SOD1) or Cu, Zn SOD, present in the cell cytosol is the
most abundant SOD in the eye [8]. SOD1 reduces oxidative
stress in the retina by converting free oxygen radicals into
hydrogen peroxide, which is further broken down into water
by enzymes such as glutathione peroxidase or catalase. SOD1-
deficient mice exhibit key symptoms of human AMD, such as
drusen, choroidal neovascularization, and retinal pigment epi-
thelium dysfunction, suggesting a critical role for SOD1 in
protecting the retina from age-related degeneration and the
potential of SOD1 gene-mediated AMD therapy [9]. The ob-
jective of the study was to develop a highly efficient, non-
toxic, nonviral vector for the retinal delivery of SOD1 gene.
Nonviral vectors are considered advantageous for gene
therapy due to their ability to minimize the host immune re-
sponse, which is a major concern for viral vectors. A number
of nonviral gene delivery systems, particularly nanoparticle
systems, have been developed so far using polymers (e.g., poly
(D,L-lactic-co-glycolic acid; PLGA) [10], poly(L-lysine) [11],
and chitosan [12]), lipids (e.g., ethyldimyristoylphosphatidyl-
choline (EDMPC) [13], 1,2-distearyloxy-N,N-dimethyl-3-
aminopropane (DSDMA) [14], and 1,2-dioleoyl-sn-glycero-
3-trimethylammoniumpropane (DOTAP) [15]), and
dendrimers (e.g., polypropylenimine (PPI) [16] and
polyamidoamine (PAMAM)). Although promising, the
nonviral gene delivery systems have hitherto achieved mod-
erate success due to their relatively low transfection efficiency
and the safety issues associated with the carrier materials. For
nonviral vectors, several hurdles are to be overcome at the
cell level before efficient gene transfection is achieved. Ide-
ally, nonviral vectors should protect the plasmid against deg-
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Purpose: To assess the potential of human serum albumin nanoparticles (HSA NP) as a nonviral vector for ocular delivery
of Cu, Zn superoxide dismutase (SOD1) gene.
Methods: Cu, Zn superoxide dismutase (SOD1) gene-encapsulated nanoparticles (NP) were developed using human
serum albumin (HSA), an endogenous protein, by a desolvation-crosslinking method. The pSOD-loaded HSA NP was
evaluated for in vitro release characteristics, stability against DNase I and vitreous humor degradation, cytotoxicity, cellu-
lar uptake mechanisms, in vitro transfection efficiency, and in vivo gene expression. In vitro studies employed cultured
human retinal pigment epithelial (ARPE-19) cells and in vivo studies employed a mouse model. For cell uptake analysis,
fluorescein isothiocyanate (FITC)-labeled human serum albumin (HSA) was used.
Results: Plasmid containing SOD1 gene was encapsulated in HSA by a desolvation-crosslinking method. Gene-loaded
HSA NP has a mean size of 120 nm, zeta potential of -44 mV, and plasmid encapsulation efficiency of 84%. At high
crosslinking degree, HSA NP sustained the in vitro release of plasmid over 6 days, and stabilized plasmid DNA against
DNase I and vitreous humor degradation. No cytotoxicity was observed in ARPE 19 cells treated with blank HSA NP at
concentrations up to 5 mg/ml for 96 h. Cellular uptake of HSA NP was via receptor-mediated endocytosis that involves
primarily caveolae-pathways. Confocal analysis indicated rapid endo/lysosomal escape of HSA NP. Further, confocal
studies indicated that HSA readily enters the cell nucleus. In vitro, pSOD-HSA NP resulted in more than 80% transfection
efficiency in ARPE-19 cells, which was 5 fold higher than Lipofectamine. HSA NP-transfected cells exhibited enhanced
SOD1 activity that was 5 fold higher than untreated cells, indicating the overexpression of the functional gene. Intravitreal
injection of HSA NP to the mouse eye at a dose of 130 ng of plasmid produced detectable level of fusion protein expres-
sion at 48 h, compared to non-detectable expression in control animals.
Conclusions: The HSA NP developed in this study offers a very promising approach for nonviral gene delivery to the
retina.
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746radation, lack cytotoxicity, facilitate cell entry of the plasmid,
escape endo/lysosome entrapment, and enable the nuclear tar-
geting of the plasmid [17]. Moreover, vectors are expected to
sustain plasmid release for maintaining stable gene expres-
sion over prolonged periods of time. Sustained gene expres-
sion is particularly important for posterior ocular disorders
where frequent intravitreal injections can cause serious side
effects including retinal detachment [18].
Among the aforementioned nonviral vectors, PLGA, the
only material approved for human application, is criticized
for incomplete DNA release at a rate far too slow compared to
the cell turnover rate [19], restricting the full utilization of the
plasmid dose. Therefore, new nonviral vectors are to be de-
veloped to overcome such problems and realize efficient gene
delivery. Human serum albumin (HSA), although approved
for parenteral use in humans, remains a less explored area for
gene delivery. In this report, we use HSA as the sole carrier
material in nanoparticles. HSA, composed of 585 amino ac-
ids with a molecular weight of 66 kDa (pI 5.8), has the unique
ability to reversibly or covalently bind a variety of endog-
enous or exogenous ligands such as long chain fatty acids,
vitamins, hormones, and metal ions with high affinity; this
allows HSA to serve as a transport and depot protein for nu-
merous compounds [20]. HSA binding often results in an in-
creased solubility in plasma, decreased toxicity, protection
against oxidation, and prolonged in vivo half-life of the bound
ligands [21]. The cellular uptake of HSA via receptor (glyco-
protein 60, also known as albondin)-mediated endocytosis
[22,23] and the endogenous nature of this protein might ren-
der it highly efficient and safe as a carrier for gene delivery. In
the eye, serum albumin filtrates through the blood-aqueous
barrier and is the major component (50% of total proteins) of
aqueous humor, which bathes the anterior side of the lens and
provides important metabolites for the growth of rapidly di-
viding lens epithelial cells [24]. Significant amount of serum
albumin was shown to pass through the aqueous humor into
lens cells and transport metabolites between lens cells, possi-
bly via a transcytotic route [25], indicating the presence of
specialized uptake mechanisms in the cells of the eye and jus-
tifying the application of HSA for ocular delivery of thera-
peutic agents. Arnedo et al. reported that HSA nanoparticles
improved the stability and nuclear accumulation of an oligo-
nucleotide in lung fibroblast (MCR-5) cells [26]. The research
of Carrabino et al. revealed that albumin boosts gene trans-
fection efficiency of a plasmid DNA-cationic polymer com-
plex in respiratory epithelial cells [27]. Our study is the first
to use HSA as single carrier material for gene delivery. In this
study, we prepared HSA nanoparticles containing a plasmid
encoding the genes for SOD1 and enhanced yellow fluores-
cence protein (pSOD) and demonstrated that these particles
enter cells via caveolae or clathrin mediated pathways, pro-
tect plasmid from biodegradation, allow plasmid escape from
lysosome entrapment, sustain plasmid release, allow nuclear
entry of HSA and potentially plasmid, and enhance gene ex-
pression and activity (Figure 1).
METHODS
Materials:  Human serum albumin, FITC-labeled human se-
rum albumin (FITC-HSA), absolute ethanol, 25% (w/v) glut-
araldehyde, trypan blue, DNase I, propidium iodide, filipin,
chlorpromazine hydrochloride, paraformaldehyde, Triton X-
100, thiazolyl blue tetrazolium bromide (MTT) salt, kanamy-
cin, Hoechst 33258, protease, HEPES, potassium acetate, mag-
nesium acetate, dithiothreitol (DTT), cytochalasin B,
phebylmethanesulfonyl fluoride (PMSF), aprotinin, leupeptin,
pepstatin, sodium acetate, ethylene glycol-bis(2-
aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA), adenos-
ine 5'-triphosphate (ATP), creatine phosphate, creatine phos-
phokinase, and protease (P8083, bacterial, 8.1 units/mg solid)
were products of Sigma-Aldrich Co. (St. Louis, MO).
Lipofectamine™ transfection reagent, DMEM/F12 cell cul-
ture medium and LysoTracker Red are products of Invitrogen
Co. (Carlsbad, CA). MicroBCA protein assay kit was provided
by Alkermes Inc. (Cambridge, MA). ARPE-19 cells were pur-
chased from American Type Culture Collection (ATCC,
Manassas, VA). A Cu, Zn superoxide dismutase and yellow
fluorescent protein fusion plasmid (pSOD-EYFP) was engi-
neered for use in these studies. Sterile deionized water was
used for all investigations.
Preparation of pSOD-EYFP plasmid:  SOD1 cDNA was
amplified by PCR and subcloned into pEYFP-N1 (Clontech,
Palo Alto, CA, USA) at the Bam HI and NheI sites. This vec-
tor contains the CMV (immediate early promoter) upstream
of the MCS. Escherichia coli transformed with the SOD1-
EYFP-N1 plasmid (pSOD) was amplified by overnight cul-
turing in LB medium supplemented with 1 mg/ml of kanamy-
cin. The plasmid was collected and purified using Endofree
Qiagen Plasmid Giga kit (Qiagen Inc., Valencia, CA) accord-
ing to the manufacturer’s protocol. Purity of the resulting plas-
mid was determined by the OD260/OD280 ratio (about 1.8-2.0).
Preparation of pSOD-encapsulated human serum albu-
min nanoparticles:  pSOD-encapsulated HSA NP was pre-
pared using a modified desolvation-crosslinking method [28].
Briefly, 1 ml of HSA aqueous solution (2%, w/v) was incu-
bated with 350 µg of pSOD solution in Tris-EDTA (TE) buffer
(pH 8.0) for 5 min at room temperature. The mixture was sub-
sequently added dropwise into ethanol (2 ml) under magnetic
stirring (1,000 rpm). HSA nanoparticles formed were imme-
diately cross-linked by the addition of either 1 or 20 µl of
10% (v/v) glutaraldehyde. The NP suspension was stirred for
12 h. Two ml of ethanol was added to the NP suspension to
remove excess glutaraldehyde. The nanoparticles were sepa-
rated by centrifugation at 48,000x g, 4 °C for 50 min (Sorvall
Evolution RC®, Thermo Electron Co., Asheville, NC). The
resulting NP pellet was resuspended in deionized water by
vortexing (Scientific Industries Inc., Bohemia, NY).
Characterization of pSOD-human serum albumin
nanoparticles:  pSOD- HSA NP were diluted in deionized
water at a volume ratio of 1: 50 and characterized for particle
size and zeta-potential using a ZetaPlus analyzer (Brookhaven
Instrument Corporation. Holtsville, NY). Transmission elec-
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tron microscopic image of HSA NP was acquired with an elec-
tron microscope (Philips-410LS, FEI Co., Hillsboro, OR) af-
ter the nanoparticles were negatively stained with Vanadium
(NanoVan®, Nanoprobes, Inc., Yaphank, NY).
For encapsulation efficiency determination, freshly pre-
pared pSOD-HSA NP suspension was centrifuged at 48,000x
g, 4 °C for 50 min. The unencapsulated pSOD in the superna-
tant was quantified by reacting with equal volume of Hoechst
33258 solution (2 µg/ml, in TNE buffer) for 5 min at room
temperature using the supernatant of blank HSA NP as a con-
trol. Fluorescence intensity of the resulting mixture was mea-
sured at 350 nm (excitation) and 450 nm (emission). The en-
capsulation efficiency of three batches of pSOD in HSA NP
was calculated by the following equation:
Encapsulation efficiency(%)=(Plasmid used-unencapsu-
lated plasmid)x100/Plasmid used
In vitro release of pSOD-human serum albumin
nanoparticles:  For in vitro release study, the NP pellet (con-
taining around 300 µg pSOD) was redispersed in 1 ml of phos-
phate buffer saline (PBS, pH 7.4) containing 0.1% (w/v) so-
dium azide and shaken at 100 rpm, in a shaker maintained at
37 °C. At predetermined time intervals, the particle suspen-
sion was spun down at 48,000x g, 4 °C for 50 min. pSOD
released in the supernatant was quantified using Hoechst as-
say. The pellet was redispersed in 1 ml of fresh PBS for con-
tinuation of the release study. Cumulative release of pSOD as
a percentage of encapsulated plasmid was calculated as a func-
tion of time.
Nuclease and vitreous liquid stability of pSOD in human
serum albumin nanoparticles:  HSA NP (containing 1 µg of
pSOD) was incubated at 37 °C for 0.5 h with either 5 µl of
DNase I solution (0.1 unit/ml) or 5 µl of protease (10 mg/ml
in PBS, pH 7.4), or 5 µl of fresh, homogenized vitreous hu-
mor obtained from bovine eyes. The DNase I degradation was
terminated by adding 5 µl of 20 mM EGTA solution (pH 8) as
DNase I inhibitor, followed by nanoparticle digestion with 5
µl of protease (10 mg/ml, essentially DNase-free) for 1 h at
37 °C. The integrity of the plasmid DNA was subsequently
analyzed by gel electrophoresis in a 1% agarose gel at 80 V
for 1.5 h.
Cytotoxicity of human serum albumin nanoparticles:
Safety of HSA NP as a gene delivery vector was evaluated by
determining its cytotoxicity in ARPE-19 cells using MTT as-
say. Lyophilized blank HSA NP (prepared following the same
protocols as pSOD-HSA NP, without the addition of pSOD)
were dispersed to concentrations ranging from 5 to 5000 µg/
ml in DMEM/F12 medium containing 10% FBS and supple-
mented with 100 mg/l of penicillin and 100 mg/l of strepto-
mycin. ARPE-19 cells were seeded in a 96 well-plate at a den-
sity of 10,000 cells/well. Twenty-four hours post-seeding, the
cells were washed thrice with PBS and incubated with HSA
NP suspensions for up to 96 h. At the end of incubation, cells
were treated with MTT salt (5 mg/ml in PBS) at 37 °C for 3 h.
The relative cell viability was measured by dissolving the
formazan crystals produced in 150 µl of DMSO and measur-
ing absorbance at 550 nm, with untreated cells considered as
100% viable.
Mechanism of cellular uptake of human serum albumin
nanoparticles:  FITC-labeled pSOD-HSA NP formulation was
prepared following the procedures described in 2.3 except that
5 mg of FITC-labeled HSA was added into the HSA solution
before NP preparation.
ARPE-19 cells were seeded in 96-well plate at a density
of 1x105 cells/well. On the third day post-seeding, the cells
were washed thrice with PBS followed by equilibration in 200
µl of serum-free medium at 37 °C or 4 °C for 30 min. Uptake
at 37 °C was initiated by replacing the serum-free medium
with 100 µl of FITC-labeled pSOD-HSA NP suspension (0.1
mg/ml in serum-free medium) together with 100 µl of either
serum-free medium, or filipin (1 µg/ml, an inhibitor for
caveolae-mediated endocytosis), or chlorpromazine (50 µM,
an inhibitor for clathrin-mediated endocytosis). Uptake at 4
°C was initiated by replacing the serum-free medium with 100
µl of FITC-labeled pSOD-HSA NP suspension (0.1 mg/ml)
together with 100 µl of HSA solution (20, 10, and 5 mg/ml).
Cells were incubated at 37 °C or 4 °C for 1 h. After removal of
the NP suspension, cells were washed thrice with cold PBS
followed by digestion in cell lysis buffer for 30 min. The fluo-
rescence intensity was measured in a plate reader at 485 nm
(excitation) and 535 nm (emission).
Uptake inhibition induced by chlorpromazine (50 µM) or
filipin (1 µg/ml) was visualized by confocal microscopy.
ARPE-19 cells were cultured on cover slips placed in 12-well
plates at a density of 10,000 cells/well. Uptake inhibition was
performed 3 days post-seeding, following the procedures de-
scribed above. At the end of uptake, cells were washed thrice
with cold PBS, followed by fixation with paraformaldehyde
(4%) and permeabilization with 0.1% Triton X-100. The con-
focal images were acquired with a Carl Zeiss confocal micro-
scope at 100X, following nuclei staining with propidium io-
dide (1 µg/ml).
Endolysosomal escape of pSOD-human serum albumin
nanoparticles:  ARPE-19 cells were seeded on cover slip
placed in a 12-well plate at 10,000 cells/well in 0.5 ml of cul-
ture medium. On the third day post seeding, cells were washed
thrice with PBS followed by incubation with FITC-labeled
pSOD-HSA NP (0.2 mg/ml) suspension containing 50 nM of
LysoTracker Red for 1 h. The cells were then washed thrice
with cold PBS and fixed with 4% of paraformaldehyde. Con-
focal microscopy was performed at 100X to locate the green
fluorescent particles and red staining for late endosome-lyso-
some in the cytoplasm.
Nuclear uptake of human serum albumin after digitonin
permeabilization:  Preparation of cytosol fractions: ARPE-19
cells growing to 85% of confluency in T-75 flasks were col-
lected by trypsinization and centrifugation (1,000x g, 4 °C, 5
min). Cell pellet was washed twice with a washing buffer (10
mM HEPES, pH 7.3, 110 mM potassium acetate, 2 mM mag-
nesium acetate, and 2 mM DTT) and suspended in 2 ml of
transport buffer (20 mM HEPES, pH 7.3, 110 mM potassium
acetate, 5 mM sodium acetate, 2 mM magnesium acetate, 1
mM EGTA, 2 mM DTT and 1 µg/ml each of aprotinin,
leupeptin, and pepstatin). Cells were lysed by 5 strokes with a
homogenizer (Tissue Tearor®, Biospec Products Inc.,
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Figure 1. Albumin nanoparticles for retinal gene delivery.  A: Scheme for the formation of pSOD-human serum albumin nanoparticles (HSA
NP) using desolvation-crosslinking method. B: Proposed mechanisms for the endocytosis and activity of pSOD-HSA NP.
749Bartlesville, OK) at an output of 20 Watts. The resulting ho-
mogenate was centrifuged at 1,500x g, 4 °C for 15 min to
remove nuclei and cell debris. The supernatant was centri-
fuged at 45,000x g, 4 °C for 60 min. The final supernatant
was dialysed against trnasport buffer followed by protein con-
tent evaluation using Micro BCA assay kit and used to main-
tain the stable composition of cytoplasm during nuclear up-
take study post permeabilization.
Cell permeabilization and nuclear uptake of FITC-HSA:
ARPE-19 cells grown on cover slip were rinsed in cold trans-
port buffer followed by immersion in ice-cold transport buffer
containing 40 µg/ml digitonin diluted from a 20 mg/ml stock
solution. The cells were allowed to permeabilize for 5 min,
after which the digitonin containing buffer was replaced with
cold transport buffer. The cover slip was then blotted and in-
cubated at 37 °C for 30 or 60 min with complete transport
buffer containing 0.5 mg/ml of FITC-HSA. The complete
transport buffer is composed of 50% cytosol, 20 mM HEPES,
pH 7.3, 110 mM potassium acetate, 5 mM sodium acetate, 2
mM magnesium acetate, 1 mM EGTA, 2 mM DTT, 1 mM
ATP, 5 mM creatine phosphate, 20 U/ml of creatine phospho-
kinase and 1 µg/ml each of aprotinin, leupeptin, and pepstatin.
At the end of incubation, the cells were washed thrice
with 1 ml of cold transport buffer and fixed with 4% paraform-
aldehyde at room temperature for 10 min. Cells were then
washed thrice with transport buffer and visualized using con-
focal microscope.
In vitro transfection:  ARPE-19 cells were seeded onto a
24-well plate at a density of 5x104 cells/well 24 h prior to the
transfection experiment. The transfection was initiated by
washing the cells twice with 1 ml of sterile PBS followed by
incubation at 37 °C with (1) 400 µl of serum-free culture me-
dium; (2) 5 µg of free pSOD in 400 µl serum-free medium;
(3) 1 µg of pSOD with 7.5 µl of Lipofectamine in 400 µl of
serum-free medium (4) HSA NP containing 1 µg of plasmid
DNA in 400 µl of serum-free medium, (5) blank HSA NP in
400 µl of serum-free medium at the equal HSA NP concentra-
tion as in (4). Treatments were terminated after 6 h incubation
and the cells were cultured in complete medium for another
42 h. Cells were trypsinized and collected by spinning down
at 1,500x g, 4 °C for 5 min. The cell pellet was redispersed in
0.5 ml of PBS and analyzed with a flow cytometer (Becton
Dickinson FACScalibur, BD Biosciences Inc., Rockville, MD)
for EYFP expression at 10,000 cell count/sample.
Superoxide dismutase 1 activity evaluation:  ARPE-19
cells were seeded on 6-well plate at a density of 2x105 cell/
well. Twenty-four hours post seeding, cells were transfected
for 6 h with pSOD, pSOD-encapsulated in HSA NP or pSOD
with 37.5 µl Lipofectamine, at a plasmid dose of 5 µg, in se-
rum-free medium. Serum-free medium and blank HSA NP (at
concentration equivalent to pSOD-HSA NP) were incubated
with the cells serving as control. At the end of transfection,
treatments were replaced by complete medium and incubated
for another 42 h.
For SOD1 activity evaluation, cells were lysed and col-
lected with a rubber policeman followed by centrifugation at
1,500x g, 4 °C for 10 min. The supernatant was subsequently
centrifuged at 100,000x g, at 4 °C for 10 min. The supernatant
was evaluated for SOD1 activity evaluation using a SOD ac-
tivity assay kit (Cayman Chemicals Inc., Ann Arbor, Michi-
gan) according to the manufacturer’s protocol.
Intravitreal administration of pSOD-loaded human se-
rum albumin nanoparticles:  Eighteen mice approximately 6
months old were injected IP with anesthesia, then they were
divided into three groups: PBS, pSOD, and pSOD-HSA NP.
Five µl PBS or about 5 µl pSOD (about 130 ng) or NP-plas-
mid (about 130 ng) was injected intravitreally, at approximately
2-3 mm posterior to the limbus in the left eye. Half of the
mice in each group were sacrificed on day 2 (48 h) and half of
the mice were sacrificed on day 7. After euthanasia using CO2,
the left eye was immediately removed, washed in PBS, and
the retina was isolated. The tissues were stored at -70 °C in
lysis buffer containing 50 mM Tris/Cl pH 7.4, 1% Triton X-
100, 0.5 mM EDTA and EGTA, 1:500 Sigma protease inhibi-
tor cocktail, and 1:1000 phosphatase inhibitor.
The retinas were homogenized in about 70 µl lysis buffer
with a sterile needle repeatedly and subjected to multiple
freeze/thaw cycles. After the tissue was thoroughly homog-
enized, the mixture was centrifuged for 1 min at 500x g to
settle insoluble debris. The supernatant was used for western
blot analysis with Mouse anti-GFP antibody (BD Biosciences,
San Jose, CA) and rabbit anti-SOD antibody (Abcam Inc.,
Cambridge, MA). In western blot analysis, GFP-SOD trans-
fected N/N1003A lens epithelial cells were used as positive
controls. For loading controls, 15 µg of β-actin was reacted
with polyclonal β-actin antibody (Abcam, Inc.).
Statistical analysis:  Data are presented as mean±standard
deviation, and analyzed by one way ANOVA with the Tukey’s
test applied post hoc for paired comparisons of means (SPSS
11, SPSS Inc., Chicago, IL).
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TABLE 1. CHARACTERISTICS OF BLANK AND PSOD-EYFP-ENCAPSULATED HSA NP FORMULATIONS
Formulation         Size (nm)   Polydispersity   Zeta potential (mV)   pSOD loading%
-----------------   ---------   --------------   -------------------   -------------
Blank HSA NP I*      158±3        0.16±0.01          -20.4±0.9           -
pSOD-HSA NP I*       157±1        0.09±0.01          -23.1±1.5           64.8±2.4
Blank HSA NP II**    116±7        0.29±0.04          -22.7±4.9           -
pSOD-HSA NP II**     122±2        0.25±0.01          -44.3±0.7           83.6±4.7
* Particles were prepared with 1 µl of 10% glutaraldehyde (low crosslinking). ** Particles were prepared with 20 µl of 10% glutaraldehyde
(high crosslinking).
750RESULTS & DISCUSSION
Preparation of SOD1-plasmid containing human serum albu-
min nanoparticles:  In this study, a desolvation-crosslinking
process was employed for the preparation of HSA nanoparticles
(HSA NP) [26,29] as illustrated in Figure 1A, with major
modification in two aspects: first, 2% (w/v) HSA aqueous so-
lution was added to two volumes of ethanol under high speed
magnetic stirring. The previously reported method, on the other
hand, added ethanol to aqueous HSA solution [29]. In our pro-
cedure, with rapid escape of H2O to the organic phase, the
surface tension of the protein molecules promotes the instant
formation of nanoparticles. Second, 0.1 instead of the reported
0.002 mg glutaraldehyde/mg HSA [29], the NP crosslinking
reagent, was used. This procedure reduces the HSA NP size
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Figure 2. Albumin nanoparticles are non-toxic, protect plasmid from degradation, and sustain gene delivery.  A: Human serum albumin
nanoparticles (HSA NP) crosslinked with 1 µl of 10% (w/v) glutaraldehyde. B: HSA NP crosslinked with 20 µl of 10% (w/v) glutaraldehyde.
Particles were negatively stained with Vanadium before transmission electron microscopic (TEM) imaging. C: HSA NP sustains in vitro
plasmid release. Cumulative in vitro release (%) of pSOD from HSA NP with low and high crosslinking degree is shown. Data are presented
as mean±SD, n=3. D: Enhanced stability of pSOD against DNase I and vitreous humor degradation after HSA NP encapsulation. Electro-
phoretic mobility analysis of pSOD-encapsulated HSA NP following 30 min incubation with nuclease, protease, or bovine vitreous humor. E:
Lack of cytotoxicity of HSA NP in ARPE-19 cells. Relative viability of ARPE-19 cells treated with HSA NP for up to 96 h is shown. Cell
viability was determined by MTT assay after HSA NP exposure. Data are expressed as mean±SD, n=8.
751from the reported >200 nm to about 120 nm, as shown in Table
1. Further, the pSOD encapsulation efficiency increased from
64 to 84%, with an increase in the extent of crosslinking. As
shown in Table 1, the size of pSOD-HSA NP decreased from
160 to 120 nm when the amount of glutaraldehyde used was
increased from 0.002 to 0.1 mg/mg protein, which was ac-
companied by a decrease of zeta potential from -20 to -44 mV.
The results indicate that high concentration of crosslinking
reagent favors the formation of more condensed particles.
Reduced particle size resulted in significantly increased sur-
face area of NP, which allowed more surface adsorption of
negatively charged pSOD and contributed to decreased zeta
potential that is beneficial to the particle stability. Influence
of pSOD encapsulation towards zeta potential was also re-
flected by the higher zeta potential of pSOD-loaded NP rela-
tive to blank NP.
 The structural difference of particles with low and high
crosslinking degree was clearly evident in the TEM images
(Figure 2A,B), where high crosslinking particles exhibited a
more condensed structure compared with particles with low
crosslinking degree.
Human serum albumin nanoparticles sustain plasmid re-
lease:  In vitro release of pSOD from HSA NP was evaluated
by dispersing freshly prepared NP in 1 ml of PBS containing
0.1% sodium azide followed by shaking at 37 °C, 100 rpm. At
predetermined time intervals, particle suspension was centri-
fuged at 48,000x g, 4 °C for 50 min, and the supernatant evalu-
ated for plasmid concentration using Hoechst 33258. As shown
in Figure 2C in vitro pSOD release from HSA NP with low
crosslinking and a particle size of about 160 nm, is a biphasic
curve including a fast-release phase, during which 65% of the
drug load was released in the first 6 h, and a slow but steady
release phase, accounting for the release of the remaining plas-
mid load in the next 44 h. The fast-release phase is attribut-
able to immediate desorption of surface-adhered plasmid, and
the dissociation of the loosely structured region in the
nanoparticles. And the slow-release phase could be due to the
release of tightly entrapped plasmid, accompanied with ma-
trix expansion and/or degradation. On the other hand, highly
crosslinked pSOD-HSA NP with a size of about 120 nm,
showed continuous release profile, with substantially lower
initial burst. In 6 h, 23% of loaded plasmid was released which
was 60% less than the burst release of 160 nm NP. The rest of
the DNA was released over a period of 6 days. On day 6, the
cumulative release accounted for almost 100% of the plasmid
encapsulated. Thus, high crosslinking degree enhances plas-
mid entrapment, surface negativity, and sustained gene deliv-
ery. Further, the particles allow complete release of the plas-
mid. Subsequent studies were primarily conducted with high
crosslinking HSA NP, unless otherwise stated.
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Figure 3. Cellular uptake of albumin nanoparticle is inhibited by low
temperature, excess free albumin, filipin, and chlorpromazine.  Cel-
lular uptake of h uman serum albumin nanoparticles (HSA NP; 0.1
mg/ml) in 1 h at 37 °C in the absence or presence of filipin (1 µg/ml),
chlorpromazine (50 µM), or free HSA (20, 10 and 5 mg/ml), and at 4
°C (Data are presented as mean±SD), n=9. * and ** indicate signifi-
cant difference from the control group at p less than or equal to 0.05,
and p less than or equal to 0.01, respectively.
Figure 4. Albumin nanoparticles enter cells via caveloae- and clathrin- mediated endocytosis.  Confocal image of cellular uptake of HSA NP
(0.1 mg/ml) at 37 °C for 1 h A without uptake inhibitor; or in the presence of B chlorpromazine (50 µM), or C filipin (1 µg/ml).
752Human serum albumin nanoparticles do not cause cyto-
toxicity:  One critical requirement for nonviral gene vector is
the ability to protect DNA against enzymatic degradation in
the biological environment. The stability of HSA NP-encap-
sulated plasmid was evaluated by gel electrophoresis. pSOD-
HSA NP was treated first with DNase I (0.1 unit/ml) or vitre-
ous humor (from bovine eye) at 37 °C for 30 min. DNase I
was then inactivated by 1 M of EGTA, and the NPs were de-
graded by incubation with 10 mg/ml protease solution at 37
°C for 1 h. The integrity of the released plasmid was deter-
mined by 1% agarose gel electrophoresis. As shown in the gel
image (Figure 2D), similar DNA bands were observed for
naked DNA and the lanes containing pSOD-HSA NP treated
with protease alone, suggesting that the plasmid did not suffer
major damage during NP preparation. Lane loaded with DNase
I digested pSOD showed no band, indicating the complete
degradation of the DNA, while plasmid treated with vitreous
humor showed a major degradation band, indicating the insta-
bility of the DNA in the vitreous humor. After DNase I or
vitreous humor and protease digestion, major DNA bands at a
position similar to pSOD were observed, revealing that the
encapsulated plasmid was intact after DNase I and vitreous
humor digestion. The gel electrophoresis result indicates that
HSA NP encapsulation enhances the plasmid stability and
makes it more resistant to DNase I and vitreous humor degra-
dation.
Human serum albumin nanoparticles does not cause cy-
totoxicity:  Cytotoxicity of blank nanoparticles was evaluated
by incubating ARPE 19 cells at a series of concentrations for
up to 96 h. The viability of HSA NP-treated cells was exam-
ined using MTT assay. As shown in Figure 2E, the percentage
of viable cell was more than 90% over 96 h at NP concentra-
tions up to 5 mg/ml. The highest concentration used in the
cytotoxicity study is more than 100 fold higher compared to
the particle concentration used for gene transfection, indicat-
ing that HSA NP is very safe as a vector for gene delivery.
Human serum albumin nanoparticles enter cells via
caveolae and clathrin mediated pathways:  Intracellular traf-
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Figure 5. Albumin nanoparticles do not co-localize with lysosomes.
Lack of lysosomal co-localization of FITC-labeled pSOD-HSA NP
(0.2 mg/ml) after 1 h incubation with ARPE-19 cells in the presence
of 50 nM LysoTracker Red.
Figure 6. Albumin accumulates rapidly in the cell nucleus.  Nuclear accumulation of FITC-labeled human serum albumin (0.5 mg/ml) in A 30
and B 60 min at 37 °C after digitonin (40 µg/ml, 0 °C, 5 min) permeabilization of ARPE-19 cells.
753ficking route is a major concern for nonviral gene vectors.
Pathways feasible for the cellular uptake of nonviral gene de-
livery vectors include: clathrin-mediated endocytosis,
caveolae-mediated endocytosis, and clathrin-, caveolae-inde-
pendent pathways [30]. It has been shown that many
polycationic and targeting moiety-conjugated gene vectors are
internalized by cells via a clathrin-mediated route [31,32]. In
this route, gene vectors are rapidly transported from clathrin-
coated vesicles to early endosomes (pH 6.3-6.8), and then to
late endosomes within minutes [25]. After 10-25 min, the vec-
tors are transferred to lysosome, where major plasmid break-
down occurs, contributing to low transfection efficiencies.
Therefore, vectors capable of escaping clathrin-mediated endo/
lysosomal entrapment and/or degradation will be advantageous
for gene delivery. Caveolae, on the other hand are cholesterol-
rich regions on the cell membrane. Cargos transported via
caveolae-dependent route are delivered to caveosomes instead
of lysosomes, and then to Golgi and endoplasmic reticulum
(ER). Along this route, the pH is maintained neutral and no
degradative end-station is reached [33], which is, therefore,
more preferable for gene delivery.
We investigated the intracellular trafficking route of HSA
NP by co-incubating FITC-labeled HSA NP with either filipin,
the caveolae transport inhibitor, or chlorpromazine, the clathrin
transport inhibitor. In addition, free HSA was added as a com-
petitive substrate for membrane albumin-receptor at 37 °C.
Further, influence of cellular energy deprivation on the par-
ticle uptake was assessed by using low temperature (4 °C). As
shown in Figure 3, free HSA showed a concentration-depen-
dent inhibition to the cell-associated fluorescence. At 20 mg/
ml, free HSA reduced the cell-associated FITC-HSA NP by
50%. Reduction in the uptake temperature from 37 to 4 °C led
to 84% decrease in particle uptake, revealing that the endocy-
tosis of HSA NP is a receptor-mediated, energy-dependent
event. At 37 °C, addition of either filipin (1 µg/ml) or chlor-
promazine (50 µM) concomitantly with HSA NP produced 56
and 44% inhibition in the particle uptake, respectively. The
results indicate that both caveolae and clathrin might be in-
volved in the endocytosis of HSA NP, with caveolae poten-
tially playing a more important role. This conclusion is fur-
ther confirmed by confocal microscopy. As shown in Figure
4, the cell-associated green fluorescent NP was reduced by
chlorpromazine and filipin, with filipin exerting a more evi-
dent inhibition. It was reported that filipin substantially re-
duces the transcelluar transport of albumin in cultured cells
and the permeability of albumin through microvessels in rat
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Figure 7. Albumin nanoparticles allow efficient in vitro gene trans-
fection and expression.  A: In vitro transfection efficiency with pSOD-
encapsulated human serum albumin nanoparticles (HSA NP) in
ARPE-19 cells. Following 6 h incubation with the gene delivery sys-
tem, transfection was assessed at 48 h post transfection using flow
cytometry (10,000 cell count per event). Data are expressed as
mean±SD for n=3. ** Indicates significant difference from the con-
trol group at p less than or equal to 0.01. B: Enhanced SOD1 activity
after cell transfection with 5 µg of pSOD encapsulated in HSA NP.
Following 6 h incubation with the gene delivery system, SOD activ-
ity was assessed 48 h post transfection using a SOD activity assay
kit. Data are expressed as mean±SD for n=3. ** Indicates significant
difference from the control group at p less than or equal to 0.01.
Figure 8. Albumin nanoparticles allow efficient in vivo retinal gene
expression of SOD1.  Western blot analysis of mouse retinas for SOD1
and EYFP on day 2 following intravitreal administration of PBS, or
pSOD, or pSOD-HSA NP containing a 130 ng dose of pSOD. The +
lane on the left indicates lysates from GFP-SOD transfected N/
N1003A lens epithelial cells.
754lung, revealing that the caveolae-dependent route plays a ma-
jor role in the cellular uptake of HSA [34]. Blomhoff et al.
reported that formaldehyde-modified albumin can be inter-
nalized by scavenger receptors and degraded in lysosome,
suggesting the involvement of clathrin route [35]. The authors
argued that formaldehyde modification led to increased nega-
tive charge to albumin molecule, which directs the molecules
to scavenger receptors and subsequently to the lysosomes, the
common cell surface binding pathway that mediates the up-
take and degradation. Our studies show the involvement of
both caveolae and clathrin pathways for the uptake of HSA
NP.
Human serum albumin nanoparticles escapes endosome/
lysosome entrapment and HSA enters cell nucleus:  To ex-
plore the potential of HSA NP to escape lysosome entrapment,
uptake of FITC-labeled pSOD-HSA NP was performed in the
presence of LysoTracker Red, a red fluorescent marker stains
specifically late-endosomes or lysosomes. Co-localization of
the two fluorophores was analyzed by confocal microscopy.
Results obtained revealed no co-localization of the green par-
ticle and red endo-lysosome after 1 h incubation, as shown in
Figure 5, indicating that pSOD-HSA NP likely entered the
cells via caveloae pathway. Alternatively, the particles may
have entered the cell via clathrin-dependent endocytotic path-
ways and then subsequently late endosomes and lysosomes.
From late endosomes and lysosomes, the HSA NP may have
rapidly escaped. The mechanism for the escape of the par-
ticles from endo/lysosome or other intracellular vesicles is
unknown at this stage.
To study the potential of HSA for nuclear transport, cells
were permeabilized with digitonin, a weak nonionic detergent
that selectively perforates cell membrane while leaving the
nuclear envelope and other subcellular organelles intact [36].
As shown in confocal images (Figure 6), 30 min incubation
with FITC-HSA resulted in strong nuclei-associated green fluo-
rescence in permeabilized ARPE-19 cells, indicating that free
HSA molecules can be internalized by cell nuclei. Although
the mechanism of the HSA-nuclear transport is unknown, it
might contribute to the nuclear uptake of HSA NP and/or frag-
ments of nanoparticles such as HSA-plasmid complexes. Pos-
sibly for this reason, investigators previously observed that
HSA can enhance gene transfection capability of
polyethyleneimine-DNA nanoparticles when admixed with the
formulation [37]. Thus, the nuclear uptake study revealed the
potential of HSA as a molecule capable of nuclear-transport
and hence, nuclear drug/gene delivery.
Human serum albumin nanoparticles facilitate gene ex-
pression in vitro and in vivo:  We studied the in vitro transfec-
tion efficacy of the pSOD-loaded HSA NP by incubating hu-
man retinal pigment epithelial (ARPE-19) cells with serum-
free medium containing pSOD alone, pSOD in Lipofectamine
or pSOD-HSA NP for 6 h, followed by 42 h incubation in
complete medium. Cells transfected with Lipofectamine served
as the positive control, and cells incubated with culture me-
dium and naked pSOD served as negative controls. Transfec-
tion efficiency was expressed as the percentage of EYFP-posi-
tive cells in a cell population. Figure 7A shows negligible trans-
fection for naked plasmid at a pSOD dose of 5 µg, suggesting
that transfection with plasmid alone is unsuccessful. On the
other hand, Lipofectamine with 1 µg of pSOD allows 15%
transfection efficiency. Interestingly, pSOD-HSA NP results
in 86% transfection efficiency, indicating that the HSA NP
formulation is about 6 fold more efficient than Lipofectamine.
Cells treated with blank HSA NP were also analyzed to quan-
tify any background contribution to the fluorescence measure-
ments. The results indicated 2% transfection efficiency, pos-
sibly due to the autofluorescence of glutaraldehyde modified
protein, which is negligible compared to the transfection effi-
ciency measures obtained with the plasmid containing HSA
NP.
To assess SOD1 functional gene expression, the activity
of Cu, Zn SOD was measured 48 h after gene transfection in
ARPE-19 cells and compared to that of untreated cells. SOD1
activity of blank HSA NP-treated cells was also evaluated as
a control to study the effect of the vector alone on SOD1 ex-
pression. As shown in Figure 7B, 6 h incubation with 5 µg
pSOD-encapsulated in HSA NP produced 5 fold higher SOD1
activity compared to untreated cells. At same plasmid dose,
Lipofectamine mediated transfection resulted in 4 fold higher
activity compared to untreated cells. However, incubation with
the same dose of naked pSOD or blank NP resulted in negli-
gible variation in SOD1 activity. It can be concluded from the
results that, in vitro, HSA NP is more efficient in mediating
the transfection of functional gene than Lipofectamine.
The in vivo transfection of the pSOD-loaded HSA NP
was studied in mouse eye. This part of the study was performed
at Kansas State University. Two days post intravitreal injec-
tion of 3 µl of HSA NP suspension at a dose of 130 ng pSOD
per eye, the fusion protein was detectable using western blot
in all eyes injected with the nanoparticle formulation (Figure
8). However, no fusion protein was detectable in animals
treated with naked pSOD. It can, therefore, be concluded that
the HSA NP formulation is effective for intravitreal gene de-
livery to the retina. Fusion protein was not detectable on day
7 in both plasmid treated and NP treated groups, indicating
the need for further optimization of the non-viral vector for
prolonged retinal gene expression. The HSA albumin vector
might result in different durations of expression when injected
in different locations. Following corneal intrastromal injec-
tion of a HSA nanoparticle formulation encapsulating a plas-
mid encoding for an intraceptor for vascular endothelial growth
factor, we recently observed more prolonged expression, last-
ing for over a month[38]. Another possible explanation for
the short duration of expression with intravitreal injection of
HSA NP in the current study is that the formulation may have
become less rigid in aqueous suspension form prior to in vivo
injections, which occurred in about a week after the prepara-
tion of the nanoparticles. In future, we will compare freshly
reconstituted lyophilized product with aqueous suspensions
stored for different periods for their influence on in vivo gene
expression.
The proposed mechanisms for the cell entry of pSOD-
HSA NP, SOD1 gene transfection, protein expression, and
effects are shown in Figure 1B.
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755Conclusions:  In summary, human serum albumin
nanoparticle encapsulating plasmid encoding Cu, Zn SOD was
developed using a modified desolvation-crosslinking method.
Particles exhibited negligible cytotoxicity and could protect
the plasmid DNA against the DNase I and vitreous humor
degradation. HSA NP is also capable of sustaining plasmid
release over 6 days in vitro. Cellular uptake of HSA NP is an
energy-dependent process mediated by both caveolae- and
clathrin-dependent endocytosis, and the HSA NP showed the
potential to exist in a lysosome-free surrounding within the
cell. Efficient gene transfection and gene expression was dem-
onstrated under in vitro and in vivo conditions. Collectively,
HSA NP overcomes several barriers associated with conven-
tional nonviral gene delivery, and shows great potential as a
gene delivery vector for successful gene therapy applications.
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